We are live on ! Find out more
RA

Royce & Associates Portfolio holdings

AUM $12.4B
1-Year Est. Return 64.17%
This Fund
S&P 500
This Quarter Est. Return
+5.39%
1 Year Est. Return
+64.17%
3 Year Est. Return
+130.04%
5 Year Est. Return
+162.55%
10 Year Est. Return
+785.5%
AUM
$15.8B
AUM Growth
-$906M
Cap. Flow
-$1.45B
Cap. Flow %
-9.17%
Top 10 Hldgs %
8.77%
Holding
1,179
New
60
Increased
359
Reduced
487
Closed
91

Top Buys

Rank Stock Value
1
KEX icon
Kirby Corp
KEX
+$50.7M
2
IPGP icon
IPG Photonics
IPGP
+$41.5M
3
SCOR icon
Comscore
SCOR
+$40.7M
4
LAZ icon
Lazard
LAZ
+$30.4M
5
EXPR
Express, Inc.
EXPR
+$28.1M

Top Sells

Rank Stock Value
1
CALM icon
Cal-Maine
CALM
+$86.8M
2
PLCE icon
Children's Place
PLCE
+$63M
3
NEWP
NEWPORT CORP
NEWP
+$61.7M
4
BKE icon
Buckle
BKE
+$48.1M
5
FINL
Finish Line
FINL
+$46.6M

Sector Composition

Rank Sector Weight
1 Industrials 28.53%
2 Technology 18.09%
3 Consumer Discretionary 17.72%
4 Financials 11.33%
5 Materials 7.32%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
RFP
976
DELISTED
Resolute Forest Products Inc.
RFP
$551K ﹤0.01%
100,000
NVTR
977
DELISTED
Nuvectra Corporation Common Stock
NVTR
$541K ﹤0.01%
+100,000
New +$538K
SPN
978
DELISTED
Superior Energy Services, Inc.
SPN
$540K ﹤0.01%
4,030
WP
979
DELISTED
Worldpay, Inc.
WP
$539K ﹤0.01%
10,000
PMD
980
DELISTED
Psychemedics Corporation
PMD
$516K ﹤0.01%
37,500
VRSK icon
981
Verisk Analytics
VRSK
$23.4B
$511K ﹤0.01%
6,400
-8,300
-56% -$606K
KIN
982
DELISTED
Kindred Biosciences, Inc.
KIN
$511K ﹤0.01%
148,000
+58,000
+64% +$205K
RAS
983
DELISTED
RAIT Financial Trust
RAS
$504K ﹤0.01%
160,545
+70,500
+78% +$180K
BSQR
984
DELISTED
BSQUARE Corporation
BSQR
$495K ﹤0.01%
83,675
PYPL icon
985
PayPal
PYPL
$46B
$494K ﹤0.01%
12,800
VOLT
986
DELISTED
Volt Information Sciences, Inc.
VOLT
$489K ﹤0.01%
65,000
SNBR
987
DELISTED
Sleep Number
SNBR
$475K ﹤0.01%
+24,500
New +$468K
CBZ icon
988
CBIZ
CBZ
$2.97B
$474K ﹤0.01%
47,000
NETI
989
DELISTED
Eneti Inc.
NETI
$472K ﹤0.01%
15,481
+7,039
+83% +$221K
FBIO icon
990
Fortress Biotech
FBIO
$83M
$457K ﹤0.01%
9,827
CIVI
991
DELISTED
Civitas Solutions, Inc.
CIVI
$457K ﹤0.01%
26,200
+5,200
+25% +$107K
BCRX icon
992
BioCryst Pharmaceuticals
BCRX
$2.09B
$453K ﹤0.01%
+160,000
New +$709K
PRSO icon
993
Peraso
PRSO
$7.02M
$445K ﹤0.01%
86
-6
-7% -$38.6K
ECOL
994
DELISTED
US Ecology, Inc.
ECOL
$442K ﹤0.01%
10,000
-44,300
-82% -$1.6M
ASPN icon
995
Aspen Aerogels
ASPN
$403M
$441K ﹤0.01%
97,996
+30,011
+44% +$136K
BELFB
996
Bel Fuse Inc Class B
BELFB
$3.35B
$441K ﹤0.01%
30,238
GENC icon
997
Gencor Industries
GENC
$249M
$437K ﹤0.01%
+44,877
New +$380K
RSPP
998
DELISTED
RSP Permian, Inc.
RSPP
$436K ﹤0.01%
+15,000
New +$352K
CCBG icon
999
Capital City Bank Group
CCBG
$866M
$435K ﹤0.01%
29,822
CDNA icon
1000
CareDx
CDNA
$2.72B
$426K ﹤0.01%
85,917
+11,503
+15% +$58.9K

Similar funds

Royce & Associates's Q1 2016 Portfolio in Review

As of Q1 2016, Royce & Associates held 1,179 positions worth $15.8B, down 5.4% from $16.8B the previous quarter. Its ten largest holdings account for 8.8% of the portfolio.

Royce & Associates withdrew a net $1.45B in Q1 2016, closing 91 positions and reducing 487 holdings. Its most notable exit was NEWPORT CORP, an estimated $61.7M position sold in full.

By sector, the portfolio is most concentrated in Industrials at 29% of assets, up from 28% a quarter earlier, followed by Technology and Consumer Discretionary.

Against the trend, Royce & Associates opened a new position in Comscore worth $33.9M.

  • Royce & Associates's largest Q1 2016 buy was Comscore: 56,347 shares worth $33.9M.
  • Royce & Associates added most to Kirby Corp in Q1 2016, an estimated $50.7M increase.
  • Royce & Associates's biggest Q1 2016 reduction was Cal-Maine, cutting an estimated $86.8M.
  • Royce & Associates fully exited NEWPORT CORP in Q1 2016, selling an estimated $61.7M.
  • Royce & Associates's ten largest holdings make up 8.8% of its $15.8B portfolio in Q1 2016.
  • Royce & Associates opened 60 new positions and closed 91 in Q1 2016.
  • Royce & Associates's portfolio value fell 5.4% quarter-over-quarter to $15.8B.

Based on Royce & Associates's 13F filing for Q1 2016, filed 11 May 2016.